Previous studies have reported that thymic carcinoma patients with a high PD-L1 expression, i.e., at least 50% of the tumor cells being PD-L1-positive, had a higher partial or complete response rate compared to those with a low PD-L1 expression after treatment with pembrolizumab [8,17]. The gene discussed is CD274; the disease is neoplasm.